Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

12. Juni 2017 08:00 ET | Quelle: Orgenesis Inc.

Orgenesis to Present at the 2017 Marcum MicroCap Conference

GERMANTOWN, MD--(Marketwired - Jun 12, 2017) - Orgenesis Inc. (OTCQB: ORGS), a vertically-integrated biopharmaceutical company with expertise and unique experience in cell therapy development and...
08. März 2017 09:00 ET | Quelle: Orgenesis Inc.

Orgenesis Provides Update Regarding AIP Cell-Based Therapy for Type 1 Diabetes, MaSTherCell Cell Manufacturing Subsidiary and Overall Financial Condition

GERMANTOWN, MD--(Marketwired - Mar 8, 2017) - Orgenesis Inc. (OTCQB: ORGS), a vertically-integrated biopharmaceutical company with expertise and unique experience in cell therapy development and...
13. Februar 2017 08:30 ET | Quelle: Orgenesis Inc.

Orgenesis Approved for Euro 12.3 Million European Grant for Further Development of Its Type 1 Diabetes Program

GERMANTOWN, MD--(Marketwired - Feb 13, 2017) - Orgenesis Inc. (OTCQB: ORGS), a fully-integrated cell therapy and contract development and manufacturing company, announced that its Belgian...
20. Januar 2017 09:00 ET | Quelle: Orgenesis Inc.

Servier Appoints MaSTherCell for the Development of its CAR-T Cell Therapy Manufacturing Platform

GERMANTOWN, MD--(Marketwired - Jan 20, 2017) - Orgenesis Inc. (OTCQB: ORGS), a fully-integrated cell therapy and contract development and manufacturing company, announced that its...
20. Oktober 2016 10:19 ET | Quelle: Orgenesis Inc.

Orgenesis CEO Vered Caplan to Present at T1D Exchange Annual Meeting

GERMANTOWN, MD--(Marketwired - Oct 20, 2016) - Orgenesis Inc. (OTCQB: ORGS), a fully integrated cell therapy and contract development and manufacturing company, announced that Orgenesis CEO, Vered...
17. August 2016 09:00 ET | Quelle: Orgenesis Inc.

Orgenesis CEO to Present at the 8th Annual Bioprocessing Summit

GERMANTOWN, MD--(Marketwired - Aug 17, 2016) - Orgenesis Inc. (OTCQB: ORGS), a fully-integrated cell therapy and contract development and manufacturing company, announced that Orgenesis management...
01. August 2016 09:00 ET | Quelle: Orgenesis Inc.

Orgenesis and Atvio Biotech Launch Joint Venture for Gene and Cell Therapy Development Services

GERMANTOWN, MD--(Marketwired - Aug 1, 2016) - Orgenesis Inc. (OTCQB: ORGS), a fully integrated cell therapy and contract development and manufacturing company (the "Company" or "Orgenesis") has...
07. Juni 2016 09:00 ET | Quelle: Orgenesis Inc.

Orgenesis and CureCell Awarded Grant From the KORIL Fund for Diabetes Research and Development

GERMANTOWN, MD--(Marketwired - Jun 7, 2016) - Orgenesis Ltd., a wholly-owned subsidiary of Orgenesis Inc. (OTCQB: ORGS), a fully integrated cell therapy and regenerative medicine company with a...
26. Januar 2015 08:48 ET | Quelle: Orgenesis Inc.

Orgenesis and Pall Corporation Receive $800,000 Grant From BIRD Foundation for Diabetes Research and Development

TEL AVIV, ISRAEL--(Marketwired - Jan 26, 2015) - Orgenesis Ltd., a wholly-owned subsidiary of Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and regenerative...
15. Oktober 2014 07:00 ET | Quelle: Orgenesis Inc.

Orgenesis Receives Patent for Potential Cure for Type 1 Diabetes

GERMANTOWN, MD--(Marketwired - Oct 15, 2014) - Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and regenerative medicine, today announced that it has received a...

Nächste Seite